The Chemours Company filed a Form 8-K with the SEC on September 9, 2026, disclosing that it had posted an investor presentation to its website for use in upcoming meetings with investors, analysts, and other interested parties.

Key Highlights

  • Filing date: September 9, 2026, under Item 7.01 Regulation FD Disclosure.
  • Presentation posted: A September 2026 Investor Presentation was furnished as Exhibit 99.1.
  • Purpose: The company disclosed the presentation will be used in connection with upcoming meetings with investors, analysts, and other interested parties.
  • Non-filed status: The filing states the furnished information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signatory: Shane Hostetter, Senior Vice President and Chief Financial Officer, signed the report on September 9, 2026.

Chemours Regulation FD Disclosure and Investor Presentation Details

The Chemours Company, a Delaware-incorporated specialty chemicals manufacturer with common stock trading on the New York Stock Exchange under the symbol CC (NYSE:CC), submitted this current report to satisfy its Regulation FD obligations. Regulation FD requires that when a company discloses material nonpublic information to certain market participants, it must make that information broadly available to the public simultaneously or promptly thereafter. By posting the presentation and filing this 8-K, Chemours complied with that requirement.

According to the filing, the September 2026 Investor Presentation was posted to the company's Investor Relations website on September 9, 2026, the same date as the report. The company disclosed it will use the presentation in connection with upcoming meetings with investors, analysts, and other interested parties. Chemours is headquartered at 1007 Market Street, Wilmington, Delaware 19801, and carries Commission File Number 001-36794. The common stock has a par value of $0.01 per share.

The filing further specifies that the furnished information, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and "it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing." The filing was signed by Chief Financial Officer Shane Hostetter in his capacity as Senior Vice President.

What Was Disclosed

Chemours filed an 8-K on September 9, 2026, reporting under Item 7.01 that it had posted a September 2026 Investor Presentation for use with upcoming investor and analyst meetings, furnished as Exhibit 99.1 and carrying a non-filed designation under the Exchange Act.